ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

Bristol No Longer Needs Yew From Public Lands, Official Says; Will Use Processed Needles

January 29, 1993

EORTC Places Same Number on Phase 2-3 Trials As In U.S.

December 12, 1986

Long-Term Estrogen Use May Increase Ovarian Cancer Risk

April 27, 2001

NCI Advisory Group, Other Cancer Meetings

June 2, 1989

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

November 7, 1980

Two Reports Offer Definitions, Plans For Comparative Effectiveness Research

July 3, 2009